Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: Results from a kidney transplant consortium

Transplantation

Volumn 93, Issue 6, 2012, Pages 624-631

  Jacobson, Pamala A ^a,b,c,d,e   Schladt, David ^f   Israni, Ajay ^f   Oetting, William S ^f   Lin, Yi Cheng ^f   Leduc, Robert ^f   Guan, Weihau ^f   Lamba, Vishal ^f   Matas, Arthur J ^f  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e NONE   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DNA; MYCOPHENOLIC ACID; STEROID; TACROLIMUS;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYP2C9 GENE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GAN GENE; GENE; GENETIC ASSOCIATION; GENOTYPE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MTRR GENE; MULTICENTER STUDY; NEPHROTOXICITY; PAX4 GENE; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; XPC GENE;

EID: 84862776591     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182461288     Document Type: Article

References (82)

1. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481.
2. Katari SR, Magnone M, Shapiro R, et al. Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. Clin Transplant 1997; 11: 237.
3. Dunn CJ, Wagstaff AJ, Perry CM, et al. Cyclosporin: An updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral) in organ transplantation. Drugs 2001; 61: 1957.
4. Scott LJ, McKeage K, Keam SJ, et al. Tacrolimus: A further update of its use in the management of organ transplantation. Drugs 2003; 63: 1247.
5. Laskow DA, Vincenti F, Neylan JF, et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: A report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 62: 900.
6. Hedayat S, Kershner RP, Su G. Relationship of whole-blood FK506 concentrations to rejection and toxicity in liver and kidney transplants. J Biopharm Stat 1996; 6: 411.
7. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
8. Ekberg H, Bernasconi C, Noldeke J, et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 2010; 25: 2004.
9. Abramowicz D, Del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16: 2234.
10. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1.
11. Walker R, Thomas M, Goodman D, et al. Combination therapy with tacrolimus and mycophenolate mofetil: Effects of early and late minimization of mycophenolate mofetil after renal transplant. Clin Transplant 2008; 22: 594.
12. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514.
13. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: Observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876.
14. Oberbauer R, Kreis H, Johnson RW, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003; 76: 364.
15. Kreis H, Oberbauer R, Campistol JM, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809.
16. Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910.
17. Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: Its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 55.
18. Tesi RJ, Elkhammas EA, Henry ML, et al. Acute rejection episodes: Best predictor of long-term primary cadaveric renal transplant survival. Transplant Proc 1993; 25: 901.
19. Lindholm A, Dahlqvist R, Groth GG, et al. A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation. Br J Clin Pharmacol 1990; 30: 443.
20. Perico N, Ruggenenti P, Gotti E, et al. In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: Insights from the MY.S.S. trial. Kidney Int 2004; 65: 1084.
21. Weber LT, Armstrong VW, Shipkova M, et al. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. Ther Drug Monit 2004; 26: 415.
22. Morris RG, Russ GR, Cervelli MJ, et al. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 2002; 24: 479.
23. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Transplantation 2001; 72: 1024.
24. Kasiske BL, Heim-Duthoy K, Rao KV, et al. The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. Transplantation 1988; 46: 716.
25. Venkataramanan R, Shaw LM, Sarkozi L, et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol 2001; 41: 542.
26. Borobia AM, Romero I, Jimenez C, et al. Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection. Ther Drug Monit 2009; 31: 436.
27. Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant 2001; 16: 1905.
28. Harada KM, Mandia-Sampaio EL, de Sandes-Freitas TV, et al. Risk factors associated with graft loss and patient survival after kidney transplantation. Transplant Proc 2009; 41: 3667.
29. de Fijter JW. Rejection and function and chronic allograft dysfunction. Kidney Int Suppl 2010; S38.
30. Li C, Yang CW. The pathogenesis and treatment of chronic allograft nephropathy. Nature Rev Nephrol 2009; 5: 513.
31. Wu O, Levy AR, Briggs A, et al. Acute rejection and chronic nephropathy: A systematic review of the literature. Transplantation 2009; 87: 1330.
32. Hawwa AF, McKiernan PJ, Shields M, et al. Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br J Clin Pharmacol 2009; 68: 413.
33. Kuypers DR, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007; 82: 711.
34. Kuypers DR, Naesens M, de Jonge H, et al. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther Drug Monit 2010; 32: 394.
35. Smith HE, Jones JP III, Kalhorn TF, et al. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet Genomics 2008; 18: 943.
36. Hauser IA, Schaeffeler E, Gauer S, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16: 1501.
37. Naesens M, Lerut E, de Jonge H, et al. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol 2009; 20: 2468.
38. Azarpira N, Aghdaie MH, Behzad-Behbahanie A, et al. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation. Exp Clin Transplant 2006; 4: 416.
39. Bandur S, Petrasek J, Hribova P, et al. Haplotypic structure of ABCB1/ MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. Transplantation 2008; 86: 1206.
40. Cattaneo D, Ruggenenti P, Baldelli S, et al. ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. J Am Soc Nephrol 2009; 20: 1404.
41. Hesselink DA, van Schaik RH, van Agteren M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008; 18: 339.
42. Quteineh L, Verstuyft C, Furlan V, et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol 2008; 103: 546.
43. Gallon L, Akalin E, Lynch P, et al. ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients. Transplantation 2006; 81: 463.
44. Hebert MF, Dowling AL, Gierwatowski C, et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 2003; 13: 661.
45. Joy MS, Hogan SL, Thompson BD, et al. Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Nephrol Dial Transplant 2007; 22: 1963.
46. Klauke B, Wirth A, Zittermann A, et al. No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation. J Heart Lung Transplant 2008; 27: 741.
47. Fukudo M, Yano I, Yoshimura A, et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 2008; 18: 413.
48. Hesselink DA, Bouamar R, van Gelder T. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. Ther Drug Monit 2010; 32: 387.
49. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamicsofcalcineurininhibitors:PartII.ClinPharmacokinet2010;49:207.
50. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68.
51. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62: 920.
52. Kuypers DR, Claes K, Evenepoel P, et al. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 2004; 75: 434.
53. Spector AA, Norris AW. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 2007; 292: C996.
54. Zhou SF, Zhou ZW, Huang M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 2010; 278: 165.
55. Wang Y, Wang C, Li J, et al. Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem. Eur J Clin Pharmacol 2009; 65: 239.
56. Nankivell BJ, Chapman JR, Bonovas G, et al. Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. Transplantation 2004; 77: 1457.
57. Luo G, Zeldin DC, Blaisdell JA, et al. Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid. Arch Biochem Biophys 1998; 357: 45.
58. Harmon DL, Shields DC, Woodside JV, et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genetic Epidemiol 1999; 17: 298.
59. Gaughan DJ, Kluijtmans LA, Barbaux S, et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis 2001; 157: 451.
60. Winkelmayer WC, Kramar R, Curhan GC, et al. Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: A prospective study. J Am Soc Nephrol 2005; 16: 255.
61. O’Leary VB, Parle-McDermott A, Molloy AM, et al. MTRR and MTHFR polymorphism: Link to Down syndrome? Am J Med Genetics 2002; 107: 151.
62. Naushad SM, Jain Jamal MN, Prasad CK, et al. Relationship between methionine synthase, methionine synthase reductase genetic polymorphisms and deep vein thrombosis among South Indians. Clin Chem Lab Med 2008; 46: 73.
63. van der Linden IJ, den Heijer M, Afman LA, et al. The methionine synthase reductase 66A>G polymorphism is a maternal risk factor for spina bifida. J Mol Med 2006; 84: 1047.
64. Winkelmayer WC, Kramar R, Sunder-Plassmann G, et al. Effects of single-nucleotide polymorphisms in MTHFR and MTRR on mortality and allograft loss in kidney transplant recipients. Kidney Int 2005; 68: 2857.
65. Feix A, Winkelmayer WC, Eberle C, et al. Methionine synthase reductase MTRR 66A>G has no effect on total homocysteine, folate, and Vitamin B12 concentrations in renal transplant patients. Atherosclerosis 2004; 174: 43.
66. Hagen W, Fodinger M, Heinz G, et al. Effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients. Kidney Int Suppl 2001; 78: S253.
67. Akoglu B, Kindl P, Weber N, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are determinant for vascular complications after liver transplantation. Eur J Clin Nutrition 2008; 62: 430.
68. Pavarino-Bertelli EC, Sanches de Alvarenga MP, Goloni-Bertollo EM, et al. Hyperhomocysteinemia and MTHFR C677T and A1298C polymorphisms are associated with chronic allograft nephropathy in renal transplant recipients. Transplant Proc 2004; 36: 2979.
69. Dorsey SG, Leitch CC, Renn CL, et al. Genome-wide screen identifies drug-induced regulation of the gene giant axonal neuropathy (Gan) in a mouse model of antiretroviral-induced painful peripheral neuropathy. Biol Res Nurs 2009; 11: 7.
70. Zhu LB, Xu Q, Hong CY, et al. XPC gene intron 11 C/A polymorphism is a predictive biomarker for the sensitivity to NP chemotherapy in patients with non-small cell lung cancer. Anti-Cancer Drugs 2010; 21: 669.
71. Sosa-Pineda B. The gene Pax4 is an essential regulator of pancreatic beta-cell development. Mol Cells 2004; 18: 289.
72. Cerf ME. Transcription factors regulating beta-cell function. Eur J Endocrinol 2006; 155: 671.
73. Park JW, Ji YI, Choi YH, et al. Candidate gene polymorphisms for diabetes mellitus, cardiovascular disease and cancer are associated with longevity in Koreans. Exp Mol Med 2009; 41: 772.
74. Gaston RS, Kasiske BL, Fieberg AM, et al. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant 2009; 9: 1811.
75. Gourishankar S, Leduc R, Connett J, et al. Pathological and clinical characterization of the ‘troubled transplant’: Data from the DeKAF study. Am J Transplant 2010; 10: 324.
76. Van Ness B, Ramos C, Haznadar M, et al. Genomic variation in myeloma: Design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. BMC Med 2008; 6: 26.
77. Hardenbol P, Baner J, Jain M, et al. Multiplexed genotyping with sequence-tagged molecular inversion probes. Nat Biotechnol 2003; 21: 673.
78. Jacobson PA, Oetting WS, Brearley AM, et al. Novel polymorphisms associated with tacrolimus trough concentrations: Results from a Multicenter Kidney Transplant Consortium. Transplantation 2011; 91: 300.
79. Israni A, Leduc R, Holmes J, et al. Single-nucleotide polymorphisms, acute rejection, and severity of tubulitis in kidney transplantation, accounting for center-to-center variation. Transplantation 2010; 90: 1401.
80. R: A language and environment for statistical computing. 2009 [cited 2011]; Available at: http://www.R-project.org.
81. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residential. Biometrika 1994; 81: 515.
82. Galwey NW. A new measure of the effective number of tests, a practical tool for comparing families of non-independent significance tests. Genet Epidemiol 2009; 33: 559.